Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
258
NCT01765283
Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 31, 2012
Completion: Apr 30, 2015
NCT02051049
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
Phase: N/A
Start: Mar 31, 2013
Completion: Feb 28, 2019
NCT02489292
Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)
Phase: Phase 2
Start: Oct 31, 2014
Completion: Mar 31, 2017
NCT02946554
Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF
Start: Dec 31, 2016
Completion: Jul 31, 2020
NCT03343756
HepaStem Long-Term Safety Registry
Start: Apr 4, 2018
Completion: May 23, 2024
NCT03963921
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Start: Apr 9, 2019
Completion: Aug 31, 2020
NCT04229901
Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)
Start: Jan 21, 2020
Completion: May 10, 2024